Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CHRS will decline by -11.92% over the next 2 Weeks and hit $1.48 by Wednesday, March 11, 2026. In that time frame, CHRS's share price is expected to range between $1.24 and $1.73.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Mar 11, 2026 | 1.24 | 1.48 | 1.73 |
| Mar 10, 2026 | 1.30 | 1.53 | 1.77 |
| Mar 9, 2026 | 1.36 | 1.60 | 1.83 |
| Mar 6, 2026 | 1.30 | 1.54 | 1.79 |
| Mar 5, 2026 | 1.33 | 1.56 | 1.80 |
| Mar 4, 2026 | 1.32 | 1.56 | 1.80 |
| Mar 3, 2026 | 1.37 | 1.62 | 1.87 |
| Mar 2, 2026 | 1.44 | 1.68 | 1.92 |
| Feb 27, 2026 | 1.38 | 1.62 | 1.87 |
| Feb 26, 2026 | 1.40 | 1.64 | 1.87 |
CHRS shares rose +0.60% in Wednesday, February 25, 2026's trading session, rising from a previous close of $1.67 to move at $1.68. The stock demonstrated notable intraday movement (see CHRS's key stats for a full breakdown), fluctuating between $1.66 and $1.74, a +4.82% trading range. While recent weeks have seen some volatility, CHRS has managed to secure a -17.65% drop over the past 2 weeks. The upward price movement was accompanied by decreased trading volume, with approximately 773.34K shares changing hands, 174.87K fewer than the previous session. This amounted to $1.30M in total market activity.
Will CHRS Continue Its Upward Trend?
According to analyst ratings and projections for CHRS, Coherus Oncology, Inc. shares are anticipated to increase by +2.73%, potentially reaching $1.73 per share by March 11, 2026. Short-term technical indicators currently suggest a neutral sentiment for CHRS. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 15 positive trading days within the past 30 sessions. Based on the CHRS stock forecast, now is a good time to buy CHRS stock because its current trading price is +13.53% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on CHRS covering social and institutional perspectives.
CHRS Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CHRS's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 39.86% to 47.02%) suggest mixed signals, with the stock in a neutral to slightly bearish momentum phase. The 50-day RSI, at 51.12%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 51.74%, maintains a neutral outlook for the long term. Insights into CHRS's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Coherus Oncology Short-Term Forecasts
CHRS Forecast For Next 5 Days
Our algorithm anticipates Coherus Oncology (CHRS) stock could hit $2.02 by Mar 04, 2026. This represents a +20.26% fall from today's price, following a -6.06% change over the past five days.
CHRS Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Coherus Oncology, Inc. (CHRS) stock over the next 30 days is largely positive. Price forecasts suggest an average target of $1.83, which would mean a +8.93% increase from the current price of $1.68. Projections for this period range from a high of $2.57 to a low of $1.26.
CHRS Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Coherus Oncology's price over the next three months point to a rise. CHRS stock is expected to peak at $5.71 on Apr 22, 2026 before potentially dipping to $3.67 on May 12, 2026. On average, CHRS is likely to trade around $4.70 in the coming 90 days.
Coherus Oncology Stock Forecast 2025
Based on our predictive models, Coherus Oncology (CHRS) is expected to trade between $3.67 and $11.97 throughout 2026. This would result in an average price of $5.95, potentially offering investors a +254.17% return from current levels.
Coherus Oncology, Inc. Monthly Forecast 2026–2027
February 2026
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in February 2026. The price is predicted to move between $4.77 and $5.02, settling at an average of $4.90. This could translate to a +191.67% gain.
March 2026
Based on current market signals, Coherus Oncology, Inc. is projected to trend march 2026. We forecast a trading range from $4.67 to $5.28, with a likely average price of $4.99. Investors could expect a potential return of +197.02%.
April 2026
Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in April 2026. The expected range spans $4.28–$5.71, with an average target of $4.95. This represents a positive outlook and a possible gain of +194.64%.
May 2026
Analyzing established trends, Coherus Oncology, Inc. looks set to move in May 2026. Projections place the stock between $3.67 and $4.79, averaging around $4.03. This suggests a +139.88% gain from current levels.
June 2026
Market indicators suggest Coherus Oncology, Inc. could experience notable changes during June 2026. Prices could fluctuate within $3.94 to $5.08, with a midpoint forecast of $4.52. The stock might deliver a +169.05% gain.
July 2026
Forecasting for July 2026, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $3.71 and $7.62, averaging $5.47. This signals a positive trajectory with potential returns around +225.60%.
August 2026
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in August 2026. The price is predicted to move between $6.64 and $8.67, settling at an average of $7.73. This could translate to a +360.12% gain.
September 2026
Based on current market signals, Coherus Oncology, Inc. is projected to trend september 2026. We forecast a trading range from $4.71 to $8.22, with a likely average price of $6.84. Investors could expect a potential return of +307.14%.
October 2026
Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in October 2026. The expected range spans $4.65–$8.83, with an average target of $7.14. This represents a positive outlook and a possible gain of +325.00%.
November 2026
Analyzing established trends, Coherus Oncology, Inc. looks set to move in November 2026. Projections place the stock between $4.44 and $7.91, averaging around $5.99. This suggests a +256.55% gain from current levels.
December 2026
Market indicators suggest Coherus Oncology, Inc. could experience notable changes during December 2026. Prices could fluctuate within $4.56 to $11.97, with a midpoint forecast of $7.82. The stock might deliver a +365.48% gain.
January 2027
Forecasting for January 2027, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $7.01 and $14.59, averaging $11.52. This signals a positive trajectory with potential returns around +585.71%.
February 2027
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in February 2027. The price is predicted to move between $5.66 and $12.20, settling at an average of $9.35. This could translate to a +456.55% gain.
CHRS's history of dividends and stock splits also plays a role in long-term investor confidence.